

DEBLASI UGO D  
Form 4  
February 03, 2006

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
DEBLASI UGO D

(Last) (First) (Middle)

APPLERA CORPORATION, 301 MERRITT 7

(Street)

NORWALK, CT 06851-1070

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
APPLERA CORP [ABI/CRA]

3. Date of Earliest Transaction  
(Month/Day/Year)

02/01/2006

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_ Director \_\_\_ 10% Owner  
\_X\_ Officer (give title below) \_\_\_ Other (specify below)

Vice President and Controller

6. Individual or Joint/Group Filing(Check Applicable Line)

\_X\_ Form filed by One Reporting Person  
\_\_\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Applied Biosystems Group Common Stock	02/01/2006		M	1,967 A	\$ 15.5552 4,233.9205	D	
Applied Biosystems Group Common Stock	02/01/2006		S <sup>(1)</sup>	93 D	\$ 28.4 4,140.9205	D	
Applied Biosystems	02/01/2006		S <sup>(1)</sup>	93 D	\$ 28.3 4,047.9205	D	

Edgar Filing: DEBLASI UGO D - Form 4

Group Common Stock							
Applied Biosystems Group Common Stock	02/01/2006	S <sup>(1)</sup>	279	D	\$ 28.25	3,768.9205	D
Applied Biosystems Group Common Stock	02/01/2006	S <sup>(1)</sup>	813	D	\$ 28.2	2,955.9205	D
Applied Biosystems Group Common Stock	02/01/2006	S <sup>(1)</sup>	522	D	\$ 28.16	2,433.9205	D
Applied Biosystems Group Common Stock	02/01/2006	S <sup>(1)</sup>	167	D	\$ 28.1	2,266.9205	D
Applied Biosystems Group Common Stock	02/02/2006	M	1,967	A	\$ 15.5552	4,233.9205	D
Applied Biosystems Group Common Stock	02/02/2006	S <sup>(1)</sup>	2	D	\$ 28.3	4,231.9205	D
Applied Biosystems Group Common Stock	02/02/2006	S <sup>(1)</sup>	46	D	\$ 28.15	4,185.9205	D
Applied Biosystems Group Common Stock	02/02/2006	S <sup>(1)</sup>	63	D	\$ 28.11	4,122.9205	D
Applied Biosystems Group	02/02/2006	S <sup>(1)</sup>	104	D	\$ 28.1	4,018.9205	D

Edgar Filing: DEBLASI UGO D - Form 4

Common Stock							
Applied Biosystems Group Common Stock	02/02/2006	S <sup>(1)</sup>	2	D	\$ 28.09	4,016.9205	D
Applied Biosystems Group Common Stock	02/02/2006	S <sup>(1)</sup>	16	D	\$ 28.08	4,000.9205	D
Applied Biosystems Group Common Stock	02/02/2006	S <sup>(1)</sup>	24	D	\$ 28.07	3,976.9205	D
Applied Biosystems Group Common Stock	02/02/2006	S <sup>(1)</sup>	39	D	\$ 28.05	3,937.9205	D
Applied Biosystems Group Common Stock	02/02/2006	S <sup>(1)</sup>	7	D	\$ 28.04	3,930.9205	D
Applied Biosystems Group Common Stock	02/02/2006	S <sup>(1)</sup>	6	D	\$ 28.03	3,924.9205	D
Applied Biosystems Group Common Stock	02/02/2006	S <sup>(1)</sup>	71	D	\$ 28	3,853.9205	D
Applied Biosystems Group Common Stock	02/02/2006	S <sup>(1)</sup>	24	D	\$ 27.99	3,829.9205	D
Applied Biosystems Group Common	02/02/2006	S <sup>(1)</sup>	67	D	\$ 27.97	3,762.9205	D

Edgar Filing: DEBLASI UGO D - Form 4

Stock							
Applied Biosystems Group Common Stock	02/02/2006	<u>S<sup>(1)</sup></u>	67	D	\$ 27.96	3,695.9205	D
Applied Biosystems Group Common Stock	02/02/2006	<u>S<sup>(1)</sup></u>	37	D	\$ 27.95	3,658.9205	D
Applied Biosystems Group Common Stock	02/02/2006	<u>S<sup>(1)</sup></u>	6	D	\$ 27.94	3,652.9205	D
Applied Biosystems Group Common Stock	02/02/2006	<u>S<sup>(1)</sup></u>	34	D	\$ 27.93	3,618.9205	D
Applied Biosystems Group Common Stock	02/02/2006	<u>S<sup>(1)</sup></u>	159	D	\$ 27.92	3,459.9205	D
Applied Biosystems Group Common Stock	02/02/2006	<u>S<sup>(1)</sup></u>	86	D	\$ 27.91	3,373.9205	D
Applied Biosystems Group Common Stock	02/02/2006	<u>S<sup>(1)</sup></u>	60	D	\$ 27.9	3,313.9205	D
Applied Biosystems Group Common Stock	02/02/2006	<u>S<sup>(1)</sup></u>	52	D	\$ 27.89	3,261.9205	D
Applied Biosystems Group Common Stock	02/02/2006	<u>S<sup>(1)</sup></u>	86	D	\$ 27.88	3,175.9205	D

Edgar Filing: DEBLASI UGO D - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Security (Instr. 3 and 4)
Applied Biosystems Group Employee Stock Options-Right to Buy	\$ 15.5552	02/01/2006		M	1,967	03/24/1999 03/24/2007	Applied Biosystems Group Common Stock
Applied Biosystems Group Employee Stock Options-Right to Buy	\$ 15.5552	02/02/2006		M	1,967	03/24/1999 03/24/2007	Applied Biosystems Group Common Stock

**Reporting Owners**

Reporting Owner Name / Address	Relationships
DEBLASI UGO D APPLERA CORPORATION 301 MERRITT 7 NORWALK, CT 06851-1070	Director 10% Owner Officer Vice President and Controller Other

## Signatures

/s/ Thomas P. Livingston, Attorney-In-Fact for Ugo D.  
DeBlasi

02/03/2006

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Reflects sale by independent third-party administrator under the issuer's Insider Diversification Program.

### Remarks:

This is the first of two forms being filed by the reporting person on February 3, 2006, to report transactions on February 1, 2006.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.